CClinicalTrials.gg
CompletedNCT03287440COPD WellnessUpdated Jun 3, 2022

Rehabilitation for Patients With COPD

An interventional study of COPD Wellness and Health Advocate in Chronic Obstructive Pulmonary Disease, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 40 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-06-03.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
40 Years to 95 Years
Sex
All
01

Study summary

This study will examine COPD Wellness, a 10-week low-intensity pulmonary rehabilitation program consisting of group and home exercise, education, and social support can improve symptoms and increase physical activity in participants with COPD who receive care within a 'safety-net' healthcare system (e.g. County Hospital). Half of the participants will also receive an adherence strategy targeted at addressing unmet social needs, while the other half will undergo the intervention without the adherence strategy.

Read the detailed description

Chronic obstructive pulmonary disease (COPD), one of the leading causes of death in the US, disproportionately affects low socioeconomic communities. While few interventions effectively modify the course of COPD and improve outcomes, pulmonary rehabilitation is the one notable exception. However, implementation of this resource-intensive program in real-life settings, and in particular, for underserved communities, has proven to be challenging. Safety-net centers that serve primarily under-insured populations lack financial resources to provide pulmonary rehabilitation.

COPD Wellness, a 10-week low-intensity pulmonary rehabilitation program consisting of group and home exercise, education, and social support, was developed to address this gap. This intervention is targeted at patients with moderate to severe COPD (GOLD Class B-D) who receive care through a safety-net health system. To be impactful, risk factors for low adherence include both disease severity and socio-environmental factors, must be addressed. As merely having a pulmonary rehabilitation program will not automatically lead to improved outcomes.

As part of this study, an adherence strategy targeted at addressing unmet social needs to improve health will also be implemented. A Health Advocates program that links social needs screening with a tiered referral and linkage process to appropriate resources will be tested to see if adherence to COPD Wellness (exercise intervention) improves by addressing competing non-medical stressors.

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Health Disparities
  • Lung Diseases
  • Self-management
  • Chronic Disease
  • Socio-economic status
03

Who can participate

Ages eligible
40 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age: Are greater than or equal to 40 years
  • Diagnosis: COPD Gold Stage Class B-D (symptomatic disease), COPD/Asthma overlap with symptoms
  • Language: English
  • Care Center: ZSFG, Community Health Center clinics, Federally Qualified Health Centers
  • Availability: Able to participate in a 10-week, weekly course at the weekly scheduled time (can defer x 1)

Exclusion criteria

Exclusion Criteria:

  • Planning to move out of the area within the next year
  • Eligible for and desire to go to full intensity pulmonary rehabilitation. Participant has Medicare Part A and B OR have San Francisco Health Plan. For those that met these criteria, we will assist with referral to program
  • Resides in any kind of long-term care facilities that is NOT Laguna Honda or the Mental Health Rehabilitation Facility
  • Has a diagnosis of interstitial lung disease, pulmonary fibrosis, or cystic fibrosis
  • Active, chronic lung infection, such as tuberculosis
  • A history of a pulmonary embolism in the year (12 months) prior to recruitment
  • History of a myocardial infarction in the year (12 months) prior to recruitment
  • In the 12 weeks prior to recruitment, has had history of unstable heart disease (including valve disease), heart failure, or uncontrolled irregular heart beat

Potential participants who have had the following will be re-assess for eligibility 6 weeks after the initial assessment:

  • A pulmonary exacerbation or worsening of COPD/Asthma symptoms in the past 6 weeks
  • History of an upper respiratory infection in the past 6 weeks
  • History of an eye, chest, or abdominal surgery within the past 6 weeks
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Active comparator
    COPD Wellness With Health Advocate

    This arm will be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD with an additional assignment of a health advocate to address unmet social needs as an adherence strategy.

    Behavioral: COPD Wellness · Behavioral: Health Advocate

  • Active comparator
    COPD Wellness

    This arm will only be given low-intensity pulmonary rehabilitation, COPD Wellness, for individuals with moderate-to-severe COPD.

    Behavioral: COPD Wellness

Interventions

  • BehavioralCOPD Wellness

    This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.

  • BehavioralHealth Advocate

    The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources

05

What researchers measure

Primary outcomes

  1. Change from Baseline 6 Minute Walk Test at End of Intervention

    Standardized test to measure distance walked in 6 minutes

    Time frame: End of Intervention, an average of 4 months

  2. Change from Baseline COPD Assessment Test (CAT) at End of Intervention

    Questionnaire assessing COPD symptoms and quality of life

    Time frame: End of Intervention, an average of 4 months

Secondary outcomes

  1. Change from Baseline number of exacerbations of COPD at End of Intervention

    Exacerbation defined as a visit to an urgent care or emergency department for COPD, a hospitalization for COPD, or a prescription of an oral steroid for worsening COPD symptoms

    Time frame: End of Intervention, an average of 4 months

  2. Change from Baseline number of exacerbations of COPD at 12 months

    Exacerbation defined as a visit to an urgent care or emergency department for COPD, a hospitalization for COPD, or a prescription of an oral steroid for worsening COPD symptoms

    Time frame: 12 months

  3. Change in baseline Smoking status at end of intervention

    Have you smoked a cigarette in the past 30 days

    Time frame: End of Intervention, an average of 4 months

  4. Change in baseline Smoking status at 12 months

    Have you smoked a cigarette in the past 30 days

    Time frame: 12 months

  5. Change from baseline D-12 evaluation at end of intervention

    Evaluates dyspnea symptoms and increased ease of activities of daily living as related to COPD symptoms

    Time frame: End of Intervention, an average of 4 months

  6. Change from baseline D-12 evaluation at 12 months

    Evaluates dyspnea symptoms and increased ease of activities of daily living as related to COPD symptoms

    Time frame: 12 months

  7. Change in baseline Patient Health Questionnaire (PHQ-)8 at End of Intervention

    Diagnoses of depressive disorders and depression severity

    Time frame: End of Intervention, an average of 4 months

  8. Adherence

    Number of classes attended by the participant

    Time frame: Assessed during 10-week COPD Wellness Intervention

  9. Change from Baseline 6 Minute Walk Test at 12 months

    Standardized test to measure distance walked in 6 minutes

    Time frame: Baseline and 12 months

  10. Change from Baseline COPD Assessment Test (CAT) at 12 months

    Measure of COPD symptoms and quality of life

    Time frame: Baseline, 12 months

06

Study locations

1 site
  • Zuckerberg San Francisco General Hospital and Trauma Center
    San Francisco, California 94110, United States
07

References and documents

Publications

  • Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000 Aug 15;109(3):207-12. doi: 10.1016/s0002-9343(00)00472-1. PubMed 10974183 ↗
  • Baumann HJ, Kluge S, Rummel K, Klose H, Hennigs JK, Schmoller T, Meyer A. Low intensity, long-term outpatient rehabilitation in COPD: a randomised controlled trial. Respir Res. 2012 Sep 27;13(1):86. doi: 10.1186/1465-9921-13-86. PubMed 23017153 ↗
  • Selzler AM, Simmonds L, Rodgers WM, Wong EY, Stickland MK. Pulmonary rehabilitation in chronic obstructive pulmonary disease: predictors of program completion and success. COPD. 2012 Aug;9(5):538-45. doi: 10.3109/15412555.2012.705365. PubMed 23030585 ↗
  • Fischer MJ, Scharloo M, Abbink JJ, van 't Hul AJ, van Ranst D, Rudolphus A, Weinman J, Rabe KF, Kaptein AA. Drop-out and attendance in pulmonary rehabilitation: the role of clinical and psychosocial variables. Respir Med. 2009 Oct;103(10):1564-71. doi: 10.1016/j.rmed.2008.11.020. Epub 2009 May 29. PubMed 19481919 ↗
  • Rochester CL, Vogiatzis I, Holland AE, Lareau SC, Marciniuk DD, Puhan MA, Spruit MA, Masefield S, Casaburi R, Clini EM, Crouch R, Garcia-Aymerich J, Garvey C, Goldstein RS, Hill K, Morgan M, Nici L, Pitta F, Ries AL, Singh SJ, Troosters T, Wijkstra PJ, Yawn BP, ZuWallack RL; ATS/ERS Task Force on Policy in Pulmonary Rehabilitation. An Official American Thoracic Society/European Respiratory Society Policy Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1373-86. doi: 10.1164/rccm.201510-1966ST. PubMed 26623686 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03287440
Lead sponsor
University of California, San Francisco
Collaborators
Kaiser Permanente, Nina Ireland Program in Lung Health
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
Sep 1, 2017
Primary completion
Apr 30, 2020
Completion
Jul 30, 2020
Last update
Jun 3, 2022

Study contacts

Neeta Thakur, MD, MPH
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion